Skip to main content

Table 1 Patient characteristics

From: Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

  Overall
(N = 10)
Stable disease
(N = 4)
Progressive disease
(N = 6)
Age years median [range] 63 [19–75] 69 [19–75] 60 [42–73]
Male N (%) 4/10 (40%) 1/4 (25%) 3/6 (50%)
RET
 Wild-type N (%) 6/10 (60%) 3/4 (75%) 3/6 (50%)
 Unknown N (%) 4/10 (40%) 1/4 (25%) 3/6 (50%)
Disease extent
 Moderate 8/10 (80%) 2/4 (50%) 6/6 (100%)
 Extensive 2/10 (20%) 2/4 (50%) 0/6 (0%)
Tumormarkers
 Calcitonin DT years, [range] 2.4 [0.6–4.1] 0.8 [0.6–4.1] 2.6 [2.4–2.9]
 CEA DT years, [range] 1.9 [0.6–7.4] 1.9 [1.2–2.1] 4.0 [0.6–7.4]
PRRT indication
 PD 8/10 (70%) 3/4 (75%) 5/6 (83%)
 Tumor localization 2/10 (30%) 1/4 (25%) 1/6 (17%)
WHO
 1 8/10 (80%) 3/4 (75%) 5/6 (83%)
 3 2/10 (20%) 1/4 (25%) 1/6 (17%)
Hormonal functioning 3/10 (30%) 1/4 (25%) 2/6 (33%)
Endpoints
 Death from MTC 7/10 2/4 (50%) 5/6 (83%)
 Death other cause 1/10 1/4 (25%) 0/4 (0%)
 Alive 2/10 1/4 (25%) 1/4 (25%)
  1. Abbreviations: CEA, carcinoembryonic antigen; DT, doubling time; MTC, medullary thyroid carcinoma; N, number; PRRT, peptide receptor radionuclide therapy; RET, rearranged during transfection; WHO, world health organization performance status
  2. Footnote:
  3. ❶ Intracardial metastasis and biochemical progression; inoperable cervical tumour load
  4. ❷ Ectopic ACTH; PTH-rp; dopamine
  5. ❸ Fibrosarcoma